UCLA CARE Center
Offering state-of-the-art medical care and clinical trials for people living with HIV and AIDS.
About UCLA CARE Center
The UCLA Center for Clinical AIDS Research and Education (CARE) provides state-of-the-art medical care and conducts clinical trials for people living with HIV and AIDS. Our highly trained, nationally recognized physicians are leaders in the field of HIV Medicine, Infectious Diseases, Oncology and other areas relevant to the health of our patients. The CARE Center’s research team is committed to conducting a broad program of ethical and high quality clinical, behavioral and prevention research to promote the health of people living with or at risk for acquiring HIV and other infectious diseases.
A5418: Study of Tecovirimat for Human Monkeypox Virus
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
MAGI: Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection.
New study for the treatment of latent CMV infection in HIV positive adults.
This is an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on antiretroviral therapy (ART)-mediated suppression.
2022 IAS-USA Recommentations on Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
A panel of volunteer expert physician scientists were appointed to update the 2020 consensus recommendations. Relevant evidence in the literature (PubMed and Embase searches, which initially yielded 7891 unique citations, of which 834 were considered relevant) and studies presented at peer-reviewed scientific conferences between January 2020 and October 2022 were considered.
ACTIV-2/A5401 Study Results
In this study, SARS-CoV-2 RNA shedding was concordant across compartments. Age was strongly associated with viral shedding and men had slower viral clearance than women, which could explain sex differences in acute COVID-19 outcomes.
On My Mind... Reflections from the Chair Week 40: Running the Gamut
Since the onset of the COVID-19 pandemic, Dr. Kara Chew, a clinical investigator at the UCLA Center for Clinical AIDS Research and Education (CARE) and division of infectious diseases, has been leading COVID-19 clinical trials focused on developing promising outpatient treatments. She is currently the protocol co-chair of the NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/AIDS Clinical Trials Group (ACTG) A5401 and ACTIV-2d/A5407/SCORPIO-HR, both randomized controlled trials testing treatments for non-hospitalized adults with early COVID-19.
In The Know: A Community Webinar Highlighting New Insights in HIV and COVID Research
Click on the presentation title or presenter below to watch that specific presentation.
- Opening Remarks with Dr. Judith Currier
- An Update on COVID-19 Research with Dr. Eric Daar
- New Approaches in HIV Prevention with Dr. Raphael Landovitz
- An Update on COVID-19 Research with Dr. David Goodman-Mez
- An Update on HIV Cure Research with Dr. Kara Chew
- Q&A and Closing Remarks